Top Links

Articles Related to Rituximab

Treating Refractory Myasthenia Gravis with Rituximab – Case Report

Myasthenia gravis is an autoimmune disease characterized by motor plaque dysfunction due to antibodies against post-synaptic membrane proteins. Myasthenic symptoms classically wax and wane and are more intense at the end of the day, although they may be constant in severe pictures. Almost every patient have eyelid ptosis and double vision, and the majority of them also have proximal muscle weakness. Reversible cholinesterase inhibitors are the first-line treatment, but patients who do not achieve symptom control should receive immunosuppressive therapy, whose options include azathioprine, cyclosporine, mycophenolate, intravenous immunoglobulin and thymectomy, with different profiles of efficacy, safety and tolerability.
View complete article: PDF  |  Full-text

HCV in Lymphoid Neoplasms

HBV carrier cases
View complete article: PDF  |  Full-text

Vasculitis Associated with Chronic Lymphocytic Leukemia

A patient is present who has chronic lymphocytic leukemia (CLL) and developed a vasculitis involving the skin and large vessels along with immune complex mediated glomerulosclerosis. Both vasculitis and immune complex nephritis are rare manifestations of CLL.
View complete article: PDF  |  Full-text


Editorial Board Members Related to Rituximab

BRUCE D CHESON

Professor of Medicine
Division of Hematology and Oncology
Georgetown University Hospital
United States
Submit Manuscript


Open Access Journals

View All Journals